IDXX vs. BSX, SYK, MDT, BDX, EW, RMD, DXCM, STE, PODD, and BAX
Should you be buying IDEXX Laboratories stock or one of its competitors? The main competitors of IDEXX Laboratories include Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), ResMed (RMD), DexCom (DXCM), STERIS (STE), Insulet (PODD), and Baxter International (BAX). These companies are all part of the "health care equipment" industry.
IDEXX Laboratories vs.
Boston Scientific (NYSE:BSX) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership.
Boston Scientific has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.
89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 0.5% of Boston Scientific shares are owned by company insiders. Comparatively, 1.0% of IDEXX Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Boston Scientific received 529 more outperform votes than IDEXX Laboratories when rated by MarketBeat users. However, 71.66% of users gave IDEXX Laboratories an outperform vote while only 69.98% of users gave Boston Scientific an outperform vote.
Boston Scientific has higher revenue and earnings than IDEXX Laboratories. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Boston Scientific currently has a consensus price target of $116.00, indicating a potential upside of 16.90%. IDEXX Laboratories has a consensus price target of $536.00, indicating a potential upside of 1.91%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than IDEXX Laboratories.
IDEXX Laboratories has a net margin of 22.78% compared to Boston Scientific's net margin of 11.07%. IDEXX Laboratories' return on equity of 55.82% beat Boston Scientific's return on equity.
In the previous week, Boston Scientific had 21 more articles in the media than IDEXX Laboratories. MarketBeat recorded 35 mentions for Boston Scientific and 14 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.57 beat Boston Scientific's score of 1.21 indicating that IDEXX Laboratories is being referred to more favorably in the news media.
Summary
Boston Scientific beats IDEXX Laboratories on 10 of the 19 factors compared between the two stocks.
Get IDEXX Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IDEXX Laboratories Competitors List
Related Companies and Tools
This page (NASDAQ:IDXX) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy IDXX Stock Free IDXX Stock Alerts